PT  - JOURNAL ARTICLE
AU  - Andersen, Michael Aagaard
AU  - Sotty, Florence
AU  - Jensen, Poul Henning
AU  - Badolo, Lassina
AU  - Jeggo, Ross
AU  - Smith, Garrick Paul
AU  - Christensen, Kenneth Vielsted
TI  - Long-term exposure to PFE-360 in the AAV-α-synuclein rat model: findings and implications
AID  - 10.1101/465567
DP  - 2018 Jan 01
TA  - bioRxiv
PG  - 465567
4099  - http://biorxiv.org/content/early/2018/11/12/465567.short
4100  - http://biorxiv.org/content/early/2018/11/12/465567.full
AB  - Treatment of Parkinson’s disease is reliant on symptomatic treatments, without any option to slow or halt disease progression. Mutations in LRRK2 and α-synuclein are known risk factors for Parkinson’s disease. Presence of α-synuclein aggregates at autopsies in both idiopathic and most G2019S cases is suggestive of a common disease pathogenesis. LRRK2 and α-synuclein interaction is hypothesized to play a pivotal role in the pathological mechanisms and inhibitors of LRRK2 are investigated as novel disease modulatory treatments in the clinic. However, preclinical in vivo evidence of a beneficial effect of LRRK2 inhibition is mixed and limited. This study increases our understanding of LRRK2 as a mediator of neuronal dysfunction and the potential of LRRK2 as a promising target in PD.